Prostate cancer screening only for 'a few thousand' high risk men

UK screening advisers have recommended that prostate cancer screening should be limited to only a small group of men at unusually high inherited risk. The National Screening Committee says invitations for regular checks should go to men with a BRCA2 gene variant and a family history of breast, ovarian, pancreatic or prostate cancer. For other groups, including many men who are understandably anxious about the disease, the committee concluded that the evidence still does not show that the benefits outweigh the harms. The final advice follows months of public pressure from charities, patients and high-profile campaigners for a wider national programme.

Why a narrow programme was recommended

Prostate cancer is the most common cancer in men in the UK and causes about 12,000 deaths each year. Screening means testing people who do not have symptoms, usually beginning with a prostate specific antigen, or PSA, blood test and sometimes followed by an MRI scan. The challenge is that PSA testing can detect cancers that would become dangerous, but it can also uncover slow-growing tumours that would never have threatened a man's life.

The committee's review found that screening 1,000 men in their 50s would prevent two prostate cancer deaths over 15 years, but would also lead to 20 men being diagnosed with cancers that would never need treatment. Some of those men would then undergo surgery or radiotherapy unnecessarily, with risks that can include urinary leakage, erectile problems and lasting psychological stress. Advisers said medicine still cannot reliably separate harmless prostate cancers from those that need urgent treatment. That uncertainty turns a simple sounding blood test into a difficult population-health decision, because a diagnosis can trigger invasive treatment long before danger is clear.

The proposed high-risk pathway is therefore much narrower than campaigners had hoped. Eligible men would be invited for a PSA test every two years between the ages of 45 and 61, and the BBC reports that only a few thousand men a year are expected to fall into that category. Ministers in England, Wales, Scotland and Northern Ireland must make the final decision on whether to implement the recommendation.

The debate is not over. Researchers are studying better blood tests, imaging, artificial intelligence tools and the UK Transform trial, which may clarify whether screening should be expanded in future, including for Black men who face a higher risk of developing prostate cancer. The recommendation is about symptom-free screening, not about ignoring warning signs; anyone with urinary changes, pain or concern about family history should seek medical advice. That distinction can be easy to miss when screening headlines move faster than clinical nuance. For now, the advice reflects a cautious screening principle: invite people only when the test pathway is likely to help more than it harms. Source: BBC Health.